Bladerunner, >>> PYMX <<<
From the most recent CEO comments, it sounds like he's looking to partner the heptagonist program, or some ex-US rights. With solid Phase 2 results there should be considerable interest.
They ended 2011 with $21.4 mil, and burn approx $4 mil/quarter, so enough cash to last until early 2013, plus some additional cash likely from the exercise of outstanding warrants. But some type of pharma deal this year could bring in significant non dilutive cash.
They definitely want to keep the N.Amer antibiotic rights. The antibiotic platform is a huge breakthrough with broad applications.
Market Data 
Markets 
AI
